Center on Health Equity & Access

Clinical

Health Care Cost

Health Care Delivery

Insurance

Policy

Technology

Value-Based Care

News

All News

Press Releases

Product Approvals and Launches

Video

All Video Types

AJMC TV

Insights

OnLocation

Payer Perspectives

Peer Exchange

Post Conference Perspectives

Stakeholder Summit

Podcasts

Conferences

Conference Coverage

Conference Listing

Journals

All Journals

The American Journal of Managed Care

Population Health, Equity & Outcomes

Evidence-Based Oncology

About Supplements and Featured Publications

Supplements and Featured Publications Issues

Submit a Manuscript

Events

Institute for Value-Based Medicine

Patient-Centered Oncology Care

Resources

Interactive Tools

Clinical Spotlight

Microsites

About AJMC

AJMC Staff

Anniversary

Seema Sonnad Award

Strategic Alliance Partners

Subscribe

Articles

Tim Mok, PharmD, BCPS, BCOP, malignant hematology pharmacy research analyst at Kaiser Permanente, discussed his perspective on the balance between clinical outcomes and cost considerations. 

Dr Tim Mok: A Pharmacist's Perspective on Balancing Costs and Outcomes

Skylar is an associate editor for The American Journal of Managed Care® (AJMC®) and The Center for Biosimilars®, and joined AJMC® in 2020. She is responsible for covering all aspects of the ever-changing global biosimilar industry and produces content that is accessible and informative for all health care stakeholders.

She has a BA in journalism and media studies from Rutgers University. You can connect with Skylar on 

Videos

Tiago Biachi, MD, PhD, discusses the challenges of treating gastrointestinal (GI) cancers, particularly the limited effectiveness of immunotherapy for "cold tumors" and the need to make them more responsive to immune treatments.

Empowering Patients With GI Cancer: Overcoming Immunotherapy Limitations

Jared is a freelance writer for The American Journal of Managed Care® (AJMC®), and previously worked as a senior editor for HCPLive® at MJH Life Sciences®.

He has an MA from University of Sioux Falls. You can connect with Jared on 

Patients with generalized myasthenia gravis experienced durable improvements across measures of efficacy and regardless of the time since they were diagnosed. 

Efgartigimod Leads to Sustained Myasthenia Gravis Improvement

A Mendelian analysis supports the idea that hyperuricemia may be an important risk factor for pulmonary arterial hypertension (PAH). 

High Uric Acid Appears to Have Causal Role in PAH

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms.

About

Contact

Editorial Boards

Advertise

Do Not Sell My Information

Terms & Conditions

Privacy Policy

AJMC - Managed Care News, Research, and Expert Insights

Facebook

Twitter

LinkedIn

Instagram

Specialty Area

Biosimilars

Cardiorenalmetabolic

Dermatology

Gastroenterology

Hematology

Hepatology

Immunology

Infectious Disease

Mental Health

Neurology

Obesity

Oncology

Ophthalmology

Pulmonology

Rare Disease

Respiratory

Rheumatology

Women's Health

Spotlight

Free In-Person Regional Events Focused on Oncology and Population Health

Topics

Digital Health

Formulary

Gene Therapy

Guidelines

Health Care Administration

Population Health

All Coverage

Event Coverage

Interviews

AJMC Journals

Author Forms

Authors

Nominate a Rising Leader

View

AJMC Payer Perspectives: Collaborative Efforts in Lupus Nephritis

Video Series

Collaborating for Better Care: Healthcare Providers and Payers in Lupus Nephritis

Panelists discuss the clinical and economic burden of lupus nephritis, strategies for optimizing its management through early diagnosis and updated guidelines, and the importance of multidisciplinary care and collaboration between health care providers and payers to improve patient outcomes and access to treatment.

Panelists discuss the significant clinical and economic burdens of lupus nephritis, including the increased risk of kidney failure and death, and provide current statistics on the prevalence and incidence of lupus nephritis in various populations.

Understanding the Clinical Burden and Prevalence of Lupus Nephritis

Panelists discuss the main cost drivers of lupus nephritis treatment, comparing direct medical costs to those of other chronic conditions and examining indirect costs such as lost productivity and disability.

Cost Drivers in Lupus Nephritis

Panelists discuss the goals of therapy for lupus nephritis (LN), emphasizing the urgency of treatment to prevent renal flares and the consequences of untreated LN, as well as strategies for increasing early diagnosis and screening in patients with systemic lupus erythematosus.

Urgency to Treat in Lupus Nephritis: Goals of Therapy and Early Diagnosis Strategies

Panelists discuss the updated treatment recommendations for lupus nephritis in the Kidney Disease Improving Global Outcomes and European Alliance of Associations for Rheumatology guidelines, how they differ from previous guidelines, and the influence of these clinical guidelines on the evaluation of treatment options.

Guideline Updates in Lupus Nephritis: Impacts on Clinical Decision-Making

Panelists discuss the considerations guiding treatment choices for lupus nephritis, such as drug interactions, patient characteristics, and steroid use, and how treatment approaches might differ between nephrologists and rheumatologists.

Tailoring Lupus Nephritis Treatment: Key Considerations and Specialist Approaches

Panelists discuss the differences in efficacy and safety profiles between belimumab and voclosporin for lupus nephritis (LN) and how payers are evaluating their value, including considerations of cost-effectiveness in LN management.

Belimumab and Voclosporin: Clinical Insights and Payer Evaluations in Lupus Nephritis

Panelists discuss the challenges patients face in accessing lupus nephritis treatment and the resources available to support timely access, including how payers are facilitating care.

Improving Access to Lupus Nephritis Treatment: Strategies and Resources

Lupus Nephritis Management: Monitoring Strategies and Long-Term Study Results

Panelists discuss how health care providers and payers can collaborate more effectively to optimize lupus nephritis care.

Amit Saxena, MD, discusses how evidence-based guidelines from ACR and KDIGO have evolved to shape lupus nephritis treatment approaches, emphasizing their critical role in standardizing patient care and incorporating recent advances like new therapeutic options and refined diagnostic criteria.

From Guidelines to Practice: Advancing Lupus Nephritis Treatment

Amit Saxena, MD, discusses how personalized treatment decisions for lupus nephritis require careful consideration of patient characteristics, multidisciplinary coordination, and emerging guidelines, while acknowledging both the opportunities and challenges that lie ahead in clinical practice.

Looking Ahead: Anticipating Changes in Lupus Guidelines and Clinical Practice

I'm sorry, but I need the text of the article to provide a summary and key takeaways. Please provide the article text, and I'll be happy to assist you

Collaborating for Better Care: Healthcare Providers and Payers in Lupus Nephritis

EP: 1.Understanding the Clinical Burden and Prevalence of Lupus Nephritis

EP: 2.Cost Drivers in Lupus Nephritis

EP: 3.Urgency to Treat in Lupus Nephritis: Goals of Therapy and Early Diagnosis Strategies

EP: 4.Guideline Updates in Lupus Nephritis: Impacts on Clinical Decision-Making

EP: 5.Tailoring Lupus Nephritis Treatment: Key Considerations and Specialist Approaches

EP: 6.Belimumab and Voclosporin: Clinical Insights and Payer Evaluations in Lupus Nephritis

EP: 7.Improving Access to Lupus Nephritis Treatment: Strategies and Resources

EP: 8.Lupus Nephritis Management: Monitoring Strategies and Long-Term Study Results

EP: 9.Collaborating for Better Care: Healthcare Providers and Payers in Lupus Nephritis

EP: 10.From Guidelines to Practice: Advancing Lupus Nephritis Treatment

EP: 11.Looking Ahead: Anticipating Changes in Lupus Guidelines and Clinical Practice